DE1767275C3 - Verwendung von 2-Thio-4-uracilcarbonsäure und 4-Uracilcarbonsäure - Google Patents
Verwendung von 2-Thio-4-uracilcarbonsäure und 4-UracilcarbonsäureInfo
- Publication number
- DE1767275C3 DE1767275C3 DE1767275A DE1767275A DE1767275C3 DE 1767275 C3 DE1767275 C3 DE 1767275C3 DE 1767275 A DE1767275 A DE 1767275A DE 1767275 A DE1767275 A DE 1767275A DE 1767275 C3 DE1767275 C3 DE 1767275C3
- Authority
- DE
- Germany
- Prior art keywords
- carboxylic acid
- acid
- uracil
- thio
- uracil carboxylic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940035893 uracil Drugs 0.000 title 2
- 239000002253 acid Substances 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 18
- 229960005010 orotic acid Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- 230000002927 anti-mitotic effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ISOQUWRYYNKKGX-UHFFFAOYSA-N 4-oxo-2-sulfanylidene-1h-pyrimidine-6-carboxylic acid Chemical compound OC(=O)C1=CC(O)=NC(S)=N1 ISOQUWRYYNKKGX-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- 208000008588 molluscum contagiosum Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
- -1 thiouracil carboxylic acid Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ZXYAAVBXHKCJJB-UHFFFAOYSA-N uracil-5-carboxylic acid Chemical compound OC(=O)C1=CNC(=O)NC1=O ZXYAAVBXHKCJJB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08102/67A GB1193192A (en) | 1967-04-19 | 1967-04-19 | Pharmaceutical Compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1767275A1 DE1767275A1 (de) | 1972-04-20 |
| DE1767275B2 DE1767275B2 (de) | 1978-10-26 |
| DE1767275C3 true DE1767275C3 (de) | 1979-06-21 |
Family
ID=10106685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1767275A Expired DE1767275C3 (de) | 1967-04-19 | 1968-04-19 | Verwendung von 2-Thio-4-uracilcarbonsäure und 4-Uracilcarbonsäure |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US3608079A (enExample) |
| BE (1) | BE713858A (enExample) |
| DE (1) | DE1767275C3 (enExample) |
| FR (1) | FR7478M (enExample) |
| GB (1) | GB1193192A (enExample) |
| NL (1) | NL140733B (enExample) |
-
1967
- 1967-04-19 GB GB08102/67A patent/GB1193192A/en not_active Expired
-
1968
- 1968-04-18 NL NL686805514A patent/NL140733B/xx unknown
- 1968-04-18 US US722183A patent/US3608079A/en not_active Expired - Lifetime
- 1968-04-18 BE BE713858D patent/BE713858A/xx not_active IP Right Cessation
- 1968-04-19 FR FR148634A patent/FR7478M/fr not_active Expired
- 1968-04-19 DE DE1767275A patent/DE1767275C3/de not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| GB1193192A (en) | 1970-05-28 |
| NL140733B (nl) | 1974-01-15 |
| BE713858A (enExample) | 1968-10-18 |
| FR7478M (enExample) | 1969-12-01 |
| DE1767275A1 (de) | 1972-04-20 |
| DE1767275B2 (de) | 1978-10-26 |
| NL6805514A (enExample) | 1968-10-21 |
| US3608079A (en) | 1971-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69325998T2 (de) | Verwendung von beta-hydroxy-beta-methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen | |
| DE69304118T2 (de) | Zusammensetzung aus Omega-3 Fettsäuren enthaltendem Material und einem Glutathionstimulator zur Behandlung von Immunkrankheiten und viralen Infektionen | |
| DE2712786C2 (enExample) | ||
| DE1792295B1 (de) | Pharmazeutisches Praeparat enthaltend 1-Aminomethyladamantan | |
| DE3211587A1 (de) | Verwendung einer therapeutischen mischung zur regulierung des koerpergewichtes von menschen und saeugetieren | |
| DE60220899T2 (de) | Mittel gegen stressinduzierte krankheiten | |
| DE2818586C2 (enExample) | ||
| DE60124516T2 (de) | Kombination des lezithins mit ascorbinsäure | |
| CH638681A5 (en) | Pharmaceutical containing Echinacea and lactic acid derivatives and process for its preparation | |
| DE1767274C2 (de) | Veterinärmedizinisches Mittel zur Verhütung oder Behandlung von Viruserkrankungen | |
| DE1767275C3 (de) | Verwendung von 2-Thio-4-uracilcarbonsäure und 4-Uracilcarbonsäure | |
| DE69918152T2 (de) | Behandlung von verdauungsstörungen | |
| DE3153623C2 (enExample) | ||
| DE2525064C2 (de) | Arzneimittel mit Antiparkinson-Wirkung | |
| DE1667903C3 (de) | Verwendung von Cysteinderivaten zur Herstellung von per oral verabreichbaren Mitteln zur Bekämpfung der Seborrhoe | |
| WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| EP0018550B1 (de) | Mittel zur Behandlung von Muskelerkrankungen | |
| DE2759108A1 (de) | Verwendung von alpha -mercapto-beta- aryl-acrylsaeuren bei der steigerung des zinkgehaltes im serum und im gewebe | |
| DE69325512T2 (de) | Verwendung von remacemid zur behandlung des morbus parkinson | |
| DE2606531A1 (de) | Antihistomoniasismittel | |
| DE3780702T2 (de) | Verwendung von etodolac zur senkung des blutgehalts an harnsaeure. | |
| McNaught et al. | Effects of Sulfanilamide, Phenothiazine and Thionol in Experimental Trichinosis. | |
| DE3317280C2 (enExample) | ||
| DE69224789T2 (de) | Präparate enthaltend Isothiazol-Derivate und ein aus Torf gewonnenes bioaktives Produkt | |
| DE1792758C2 (de) | Mittel gegen Leberegel. Ausscheidung aus: 1543792 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |